Susceptibility of clinical Candida species isolates to antifungal agents by E-test, Southern Iran: A five year study
Authors:
- P BadieePBP Badiee
- A AlborziAAA Alborzi
Open Access
- 1 December 2011
- journal article
- Vol. 3 (4) , 183-188
Abstract
The incidence of fungal infections in immunocompromised patients, especially by Candida species, has increased in recent years. This study was designed to identify Candida species and determine antifungal susceptibility patterns of 595 yeast strains isolated from various clinical specimens. Identification of the isolates were determined by the API 20 C AUX kit and antifungal susceptibilities of the species to fluconazole, amphotericin B, ketoconazole, itraconazole, voriconazole, and caspofungin were determined by the agar-based E-test method. Candida albicans (48%) was the most frequently isolated species, followed by Candida kruzei (16.1%), Candida glabrata (13.5%), Candida kefyr (7.4%), Candida parapsilosis (4.8%), Candida tropicalis (1.7%) and other species (8.5%). Resistance varies depending on the species and the respective antifungal agents. Comparing the MIC90 for all the strains, the lower MIC90 was observed for caspofungin (0.5 µg/ml). The MIC90 for all Candida species were 64 µg/ml for fluconazole, 0.75 µg/ml for amphotericin B, 4 µg/ml for ketoconazole, 4 µg/ml for itraconazole, and 2 µg/ml for voriconazole. Species definition and determination of antifungal susceptibility patterns are advised for the proper management and treatment of patients at risk for systemic candidiasis. Resistance to antifungal agents is an alarming sign for the emerging common nosocomial fungal infections.Keywords
This publication has 25 references indexed in Scilit:
- Prostaglandin E2: Making More of Your MarrowCell Cycle, 2007
- Identification of Candida species isolated from patients in intensive care unit and in vitro susceptibility to fluconazole for a 3‐year periodMycoses, 2006
- In Vitro Activities of Posaconazole, Fluconazole, Itraconazole, Voriconazole, and Amphotericin B against a Large Collection of Clinically Important Molds and YeastsAntimicrobial Agents and Chemotherapy, 2006
- In Vitro Susceptibilities of Candida spp. to Caspofungin: Four Years of Global SurveillanceJournal of Clinical Microbiology, 2006
- Activities of Micafungin against 315 Invasive Clinical Isolates of Fluconazole-Resistant Candida sppJournal of Clinical Microbiology, 2006
- Candida kefyr as an Emerging Pathogen Causing Nosocomial Bloodstream Infections in Neutropenic Leukemia PatientsClinical Infectious Diseases, 2005
- In vitro activities of voriconazole (UK‐109, 496), fluconazole, itraconazole and amphotericin B against 132 non‐albicans bloodstream yeast isolates (CANARI study)Mycoses, 2004
- Amphotericin B: Time for a New "Gold Standard"Clinical Infectious Diseases, 2003
- Proficiency Testing Program for Clinical Laboratories Performing Antifungal Susceptibility Testing of Pathogenic Yeast SpeciesJournal of Clinical Microbiology, 2003
- 2002 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with CancerClinical Infectious Diseases, 2002